Member Contact: Peter Jordan
Position: Chief Executive Officer
Industry: Medtech & Digital
Biotech Resources (BTR) is commercialising a suite of tests that rapidly diagnose some of the world's most devastating diseases at point of care. Our patented tests are faster, easier and is more cost effective than current technologies. The revolutionary method was developed by the Monash University Centre for Biospectroscopy. We have achieved proof of concept for the rapid quantitative detection of pathogens and biomarkers in bodily fluids including;
o Antibiotic Susceptibility Test (AST) that detects resistance to antibiotics and antifungals in one hour post positive blood culture
o Direct detection of pathogens including parasites (malaria) and viruses (hepatitis B&C) and bacterial and fungal infection in whole blood without the need for culturing
o Biomarker detection in bodily fluids with the ability to quantitatively detect clinically relevant proteins in urine associated with diabetes and chronic kidney disease (CKD).